ZFAT
Overview
ZFAT (Zinc Finger And AT-Hook Domain Containing) encodes a transcriptional regulator with zinc finger and AT-hook domains involved in lymphocyte survival and apoptosis regulation. In the integrative DLBCL genomic landscape study of 1001 patients, ZFAT mutations were associated with poorer overall survival across all DLBCL subtypes.
Alterations observed in the corpus
- ZFAT mutations are associated with poorer overall survival (OS) across all DLBCL (n=1001, uniformly treated with rituximab-containing immunochemotherapy); identified in a multivariate combined DNA+RNA prognostic model as one of the driver genes contributing to an adverse 3-tier genomic risk classifier PMID:28985567.
Cancer types (linked)
- DLBCLNOS — mutations associated with poorer overall survival across all DLBCL subtypes in a cohort of 1001 patients; the association was identified through a combinatorial prognostic model integrating 150 driver genes with cell-of-origin and MYC/BCL2 expression PMID:28985567.
Co-occurrence and mutual exclusivity
- ZFAT mutations co-occur with the adverse prognostic signal in CD79B-mutant DLBCL; both are identified as markers of poorer survival in the combined genomic model PMID:28985567.
Therapeutic relevance
- No direct targeted therapy for ZFAT mutations is reported in the corpus; its prognostic value positions ZFAT as a candidate biomarker for risk-adapted treatment strategies in DLBCL PMID:28985567.
Open questions
- Whether ZFAT’s prognostic effect operates through a functional dependency (oncogenic or tumor-suppressor role) vs passenger mutation status is unresolved; the CRISPR screen in this study did not identify ZFAT as a functional essential gene PMID:28985567.
Sources
This page was processed by crosslinker on 2026-05-15.